Zobrazeno 1 - 2
of 2
pro vyhledávání: '"F. J. García Fructuoso"'
Autor:
Alan M. Mendelsohn, Richard C Chou, Michael E. Luggen, Alice B. Gottlieb, P. J. Mease, Saima Chohan, Ana Maria Orbai, Proton Rahman, Siba P. Raychaudhuri, F. J. García Fructuoso, Stephen J. Rozzo
Publikováno v:
Annals of the Rheumatic Diseases. 79:145-146
Background:Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate to severe plaque psoriasis and is under investigation for treatment of psoriatic arthritis (PsA).1Objectives:To evaluate effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2906765078cb825a40410abfdfa2e55
https://doi.org/10.1136/annrheumdis-2020-eular.3908
https://doi.org/10.1136/annrheumdis-2020-eular.3908
Autor:
Alan M. Mendelsohn, I.B. McInnes, Richard C Chou, Luis R. Espinoza, Michael E. Luggen, P. Nash, F. J. García Fructuoso, Stephen J. Rozzo
Publikováno v:
Annals of the Rheumatic Diseases. 79:1171.2-1171
Background:Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved in the US, EU, and Australia to treat moderate to severe plaque psoriasis. A randomised, double-blind, placebo-controlled, multiple-dose, phase 2b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::758a18aee39432eeb3fed3763f886a72
https://doi.org/10.1136/annrheumdis-2020-eular.3947
https://doi.org/10.1136/annrheumdis-2020-eular.3947